




PHARMACEUTICAL 2019

Checkpoint Therapeutics Inc.
Rank 301 of 363





PHARMACEUTICAL 2019

Checkpoint Therapeutics Inc.
Rank 301 of 363



The relative strengths and weaknesses of Checkpoint Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Checkpoint Therapeutics Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 20% points. The greatest weakness of Checkpoint Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 120% points.

The company's Economic Capital Ratio, given in the ranking table, is -85%, being 121% points below the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	24,899
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	13,093
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	373
Other Revenues	3,506
Property and Equipment	0
Research and Development	33,654
Selling, General and Administrative Expense	6,592

Output Variable	Value in 1000 USD
Assets	24,899
Liabilities	13,093
Expenses	40,246
Revenues	3,506
Stockholders Equity	11,806
Net Income	-36,367
Comprehensive Net Income	-36,367
Economic Capital Ratio	-85%